User menu

Pharmacological blockade of dopamine D(2) receptors by aripiprazole is not associated with striatal sensitization.

Bibliographic reference
Permanent URL
  1. Allikmets LH, Zarkovsky AM, Nurk AM (1981) Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment. Eur J Pharmacol 75:145–147
  2. Assie MB, Mnie-Filali O, Ravailhe V, Benas C, Marien M, Betry C, Zimmer L, Haddjeri N, Newman-Tancredi A (2009) F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release. Eur J Pharmacol 607:74–83
  3. Bardin L, Kleven MS, Barret-Grevoz C, Depoortere R, Newman-Tancredi A (2006) Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 31:1869–1879
  4. Bernardi MM, De Souza H, Palermo NJ (1981) Effects of single and long-term haloperidol administration on open field behavior of rats. Psychopharmacol Berl 73:171–175
  5. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
  6. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381–389
  7. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB, Pisani A, Tognazzi N, Bernardi G, Moratalla R, Borrelli E, Calabresi P (2003) Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 23:6245–6254
  8. Cooper SJ, Rusk IN, Barber DJ (1989) Yawning induced by the selective dopamine D2 agonist N-0437 is blocked by the selective dopamine autoreceptor antagonist (+)-UH 232. Physiol Behav 45:1263–1266
  9. Cordeaux Y, Nickolls SA, Flood LA, Graber SG, Strange PG (2001) Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 276:28667–28675
  10. Cosi C, Carilla-Durand E, Assie MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A (2006) Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol 535:135–144
  11. Fujikawa M, Nagashima M, Inoue T, Yamada K, Furukawa T (1996) Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 53:903–909
  12. Geurts M, Hermans E, Maloteaux JM (1999a) Assessment of striatal D1 and D2 dopamine receptor-G protein coupling by agonist-induced [35S]GTP gamma S binding. Life Sci 65:1633–1645
  13. Geurts M, Hermans E, Maloteaux JM (1999b) Enhanced striatal dopamine D(2) receptor-induced [35S]GTPgammaS binding after haloperidol treatment. Eur J Pharmacol 382:119–127
  14. Han M, Huang XF, Deng C (2009) Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects. Int J Neuropsychopharmacol 10:1–12
  15. Hermans E (2003) Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors. Pharmacol Ther 99:25–44
  16. Hermans E, Challiss RA, Nahorski SR (1999) Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists. Br J Pharmacol 126:873–882
  17. Hoyer D, Boddeke HW (1993) Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 14:270–275
  18. Inoue T, Domae M, Yamada K, Furukawa T (1996) Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J Pharmacol Exp Ther 277:137–143
  19. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321:105–111
  20. Ishikane T, Kusumi I, Matsubara R, Matsubara S, Koyama T (1997) Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Eur J Pharmacol 321:163–169
  21. Jong-Yih L (2009) Successful switch from clozapine to aripiprazole: a case report. J Clin Psychopharmacol 29:93–95
  22. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA (2002) The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441:137–140
  23. Jordan S, Johnson JL, Regardie K, Chen R, Koprivica V, Tadori Y, Kambayashi J, Kitagawa H, Kikuchi T (2007a) Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling. Prog Neuropsychopharmacol Biol Psychiatry 31:348–356
  24. Jordan S, Regardie K, Johnson JL, Chen R, Kambayashi J, McQuade R, Kitagawa H, Tadori Y, Kikuchi T (2007b) In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling. J Psychopharmacol 21:620–627
  25. Kane John M., Carson William H., Saha Anutosh R., McQuade Robert D., Ingenito Gary G., Zimbroff Dan L., Ali Mirza W., Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder, 10.4088/jcp.v63n0903
  26. Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS (1998) Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci USA 95:7731–7736
  27. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S (1995) 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274:329–336
  28. Kiss B, Horvath A, Nemethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyan I, Agai-Csongor E, Domany G, Tihanyi K, Adham N, Szombathelyi Z (2010) Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist–partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333:328–340
  29. Kleven MS, Barret-Grevoz C, Bruins SL, Newman-Tancredi A (2005) Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology 49:135–143
  30. Koener B, Hermans E, Maloteaux JM, Jean-Jean A, Constant EL (2007) Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole. Am J Psychiatry 164:1437–1438
  31. Kohnomi S, Suemaru K, Kawasaki H, Araki H (2008) Effect of aripiprazole on 5-HT2 receptor-mediated wet-dog shake responses and disruption of prepulse inhibition in rats. J Pharmacol Sci 106:645–650
  32. Lin H, Saisch SG, Strange PG (2006) Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br J Pharmacol 149:291–299
  33. Lindgren N, Usiello A, Goiny M, Haycock J, Erbs E, Greengard P, Hokfelt T, Borrelli E, Fisone G (2003) Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci USA 100:4305–4309
  34. Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M (1986) Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol 123:311–314
  35. Minematsu N (1995) Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats. Nihon Shinkei Seishin Yakurigaku Zasshi 15:247–252
  36. Nakai S, Hirose T, Uwahodo Y, Imaoka T, Okazaki H, Miwa T, Nakai M, Yamada S, Dunn B, Burris KD, Molinoff PB, Tottori K, Altar CA, Kikuchi T (2003) Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. Eur J Pharmacol 472:89–97
  37. Neal-Beliveau BS, Joyce JN, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207–217
  38. Nickolls SA, Strange PG (2004) The influence of G protein subtype on agonist action at D2 dopamine receptors. Neuropharmacology 47:860–872
  39. Odagaki Y, Toyoshima R (2005) 5-HT1A receptor-mediated G protein activation assessed by [35S]GTPgammaS binding in rat cerebral cortex. Eur J Pharmacol 521:49–58
  40. Odagaki Y, Toyoshima R (2007) 5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes. Clin Exp Pharmacol Physiol 34:462–466
  41. Olianas MC, Onali P (1987) Supersensitivity of striatal D2 dopamine receptors mediating inhibition of adenylate cyclase and stimulation of guanosine triphosphatase following chronic administration of haloperidol in mice. Neurosci Lett 78:349–354
  42. Prinssen EP, Kleven MS, Koek W (1999) Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacol Berl 144:20–29
  43. Semba J, Watanabe A, Kito S, Toru M (1995) Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34:785–791
  44. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411
  45. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, Kikuchi T (2005) Aripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515:10–19
  46. Tadori Y, Forbes RA, McQuade RD, Kikuchi T (2009) Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol 607:35–40
  47. Tamminga CA, Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1:141–147
  48. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007) Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32:67–77
  49. Wang LJ, Ree SC, Chen CK (2009) Courses of aripiprazole-associated tardive dyskinesia: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 33:743–744
  50. Watts VJ, Lawler CP, Gonzales AJ, Zhou QY, Civelli O, Nichols DE, Mailman RB (1995) Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists. Synapse 21:177–187
  51. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A (2006) Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 546:88–94